First Author: P.Udaondo SPAIN
Co Author(s): R. Martinez-Costa A. Cisneros-Lanuza 0 0 0 0 0 0 0 0 0
Back to previous
to determine the effectiveness of intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema (DME).
Analyze the effect of steroids as first line treatment for DME
this is a retrospective study that includes naïve patients with DME treated with dexamethasone implant; the re-treatment was based on central macular thickness (CMT) and visual acuity. The primary outcome was the percentage of patients who gained 10 or more letters from base line to month 12
51 naïve eyes of 48 patients with a short duration of symptoms (9 months) were enrolled. Both visual acuity and CMT measured by OCT improvement was statistically significant. 56 % of patients gained 10 or more letters. Security profile: 6,1% of cataract surgery, 8,7% of cataract progression and 11,9% of patients had a transient increase of intraocular pressure. No other side effects during follow up.
Intravitreal dexamethasone implant was safe and effective in the management of DME in this study.